NeurAxis Inc. proves that a smallcap biotech can deliver best-in-market care. That s more than great news for NRXS from a revenue perspective and for its patients from a treatment point of view. It.
NeurAxis Inc. stock is in rally mode, jumping over 26% since last week. Despite this significant increase, investors following this innovative biotech anticipate further growth. That optimism is.
According to an analyst at Goldman Smallcap Research, NeurAxis Inc. shares at current levels present a compelling investment opportunity. In fact, he models for a 12-month price target of $14 a.
Having just 1.21 million outstanding shares typically presents exceptionally well to a growth stock investor. But while it can fuel appreciable gains quickly, it can also cause downward pressure..